Finerenone is under clinical development by Bayer and currently in Phase III for Hypertension. According to GlobalData, Phase III drugs for Hypertension have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Finerenone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Finerenone (Kerendia,Firialta) is a nonsteroidal mineralocorticoid. It is formulated as film coated tablets, coated tablets for oral route of administration. Kerendia is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Kerendia is indicated for the treatment of chronic kidney disease with type 2 diabetes in adults, excluding patients with end-stage renal disease or on dialysis. Kerendia is indicated for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in adults, to reduce the risk of sustained eGFR decline and end-stage kidney disease.
Finerenone (BAY-948862) is under development for the treatment of diabetic nephropathy, diabetic retinopathy, chronic heart failure and chronic kidney disease, proteinuria, glomerulonephritis, hypertension in patients with type 2 diabetes. The drug candidate is administered orally as a tablet. It is a new molecular entity and acts by targeting non-steroidal mineralocorticoid receptor (MR).
It was under development for the treatment of Duchenne muscular dystrophy.
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Finerenone’s drug-specific PTSR and LoA scores, buy the report here.